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The transplantation of fetal mesencephalic cell suspensions into the brain striatal system is an emerging 
treatment for Parkinson's disease. However, one objection to this procedure is the relatively poor survival 
of implanted cells. The ability of neurotrophic factors to regulate developmental neuron survival and differ­
entiation suggests they could be used to enhance the success of cerebral grafts. We studied the effects of 
neurotrophin-3 (NT-3) or glial cell line-derived neurotrophic factor (GDNF) on the survival of dopaminergic 
neurons from rat fetal ventral mesencephalic cells (FMCs) implanted into the rat striatum. Two conditions 
were tested: (a) incubation of FMCs in media containing NT-3 and GDNF, prior to grafting, and (b) co-
grafting of FMCs with cells engineered to overexpress high levels of NT-3 or GDNF. One week after 
grafting into the rat striatum, the survival of TH+ neurons was significantly increased by pretreatment of 
ventral mesencephalic cells with NT-3 or GDNF. Similarly, co-graft of ventral mesencephalic cells with 
NT-3- or GDNF-overexpressing cells, but not the mock-transfected control cell line, increased the survival 
of graft-derived dopaminergic neurons. Interestingly, we also found that co-grafting of GDNF-overexpress­
ing cells was less effective than NT-3 at improving the survival of fetal dopaminergic neurons in the grafts, 
and that only GDNF induced intense TH immunostaining in fibers and nerve endings of the host tissue 
surrounding the implant. Thus, our results suggest that NT-3, by strongly enhancing survival, and GDNF, 
by promoting both survival and sprouting, may improve the efficiency of fetal transplants in the treatment 
of Parkinson's disease. 
Key words: Fetal ventral mesencephalic cells; Transplant; Neurotrophin-3; GDNF; Dopamine; Tyrosine 
hydroxylase; Parkinson's disease 
INTRODUCTION 
Intrastriatal grafting of fetal mesencephal ic cells 
(FMCs) containing dopaminergic neurons has been pro­
posed as t reatment to alleviate dopaminergic cell loss in 
Pa rk inson ' s disease (10,18,23) . However , the low sur­
vival of the transplanted dopaminergic neurons (12) in­
dicates that this procedure should be considered with 
caution. The identification of growth factors that im­
prove the survival and activity of nigral dopaminergic 
neurons has suggested that these molecules may im­
prove the survival of t ransplanted F M C s (22). 
Here we focus on growth factors of two different 
families: the neurotrophins and the glial cell-l ine derived 
neurotrophic factor ( G D N F ) family. The neurotrophin 
family is formed by nerve growth factor (NGF) , brain-
derived neurotrophic factor (BDNF) , neurot rophin-3 
(NT-3) , -4/5 (NT-4/5) , and -6 (NT-6) . They bind and 
activate two different types of receptor: a c o m m o n p75 
neurotrophin receptor, and a specific tyrosine kinase re­
ceptor: t rkA for N G F , t rkB for B D N F and N T - 4 / 5 , and 
trkC for NT-3 (28). 
The G D N F family of neurotrophic factors is formed 
by G D N F (37), neurturin (NTN) (33), persephin (PSP) 
(40) , and artemin (ART) (6). L igands of this family bind 
to high-affinity glycosylphosphat idylynolsi tol (GPI)-an-
chored receptors, collectively named G D N F family re­
ceptor a (GFRa) , to form a complex that subsequent ly 
activates the receptor tyrosine kinase, c-ret (29 ,31 ,53 , 
54) . G F R a l is the high-affinity receptor that is preferen-
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tially bound by G D N F (31), G F R a 2 by N T N (31), 
G F R a 4 by P S P (16), and G F R a 3 by A R T (6). 
A large number of growth factors st imulate the sur­
vival and differentiation of dopaminerg ic neurons in pr i ­
mary cultures. This includes members of the neuro­
trophin family, such as B D N F , N T - 3 , and N T - 4 
(26,27,35,58), and members of the G D N F family, such 
as G D N F (8,14,24,37), N T N (25), P S P (40), and A R T 
(6). In vivo, endogenous dopaminergic neurons also re­
spond to several of these factors, including the neuro­
trophins B D N F , N T - 3 , and N T - 4 (2,20,35), and G D N F 
(7 -9 ,11 ,13 ,45) . In addit ion, fetal dopaminergic neurons 
grafted into the rat striatum respond to B D N F (44,59), 
N T - 4 (21), and G D N F (3,19,43,46,48,50,51,56) . Be­
cause of the peptidic nature of growth factors and the 
presence of extracellular peptidases and uptake systems, 
a steady product ion of neurotrophic factors is required. 
One procedure for the cont inuous administrat ion of 
growth factors is to implant genetically modified stable 
cells that produce them. This strategy has shown that 
factors of the neurotrophin (4,35) and G D N F families 
(1,5) enhance the survival and differentiation of central 
catecholaminergic neurons in vivo. 
Here we studied the effects of NT-3 and G D N F on 
fetal mesencephal ic dopaminerg ic neurons grafted into 
the striatum. F M C s were either pretreated with NT-3 or 
G D N F prior to grafting or were co-grafted with stable 
cell l ines overexpress ing N T - 3 or G D N F (1,5). Our re­
sults show that both G D N F and NT-3 treatments im­
proved the viability of fetal dopaminergic neurons in the 
graft. 
M A T E R I A L S A N D M E T H O D S 
Animals and 6-Hydroxydopamine Lesions 
Male Sprague-Dawley rats, weighing about 250 g, 
were housed and treated according to the policy on the 
use of animals in neuroscience research published by the 
Society for Neuroscience . The experimental protocols 
were approved by a review commit tee of the Universi ty 
of Barcelona under supervision of the Government of 
Catalunya. Animals were anesthet ized with ke tamine 
hydrochlor ide (100 mg/kg, IP) + 5,6-dihydro-2-(2,6-xyl-
id ino)-4h- l ,3- th iaz ine hydrochlor ide (Rompun®, Bayer) 
(2 mg/kg, IP), and placed in a stereotaxic instrument 
with the upper incisor bar set 3.3 m m under the inter-
aural l ine. Animals were unilaterally injected with 6-hy­
droxydopamine (4 ug /u l in saline with 0 .02% ascorbic 
acid) into the right medial forebrain bundle (A: - 4 . 4 , L: 
- 1 . 3 , H: - 7 . 8 , from bregma) (42), in a vo lume of 2 ul 
and a rate of 1 u l /min. Animals injected with an equal 
vo lume of saline + ascorbate were used as controls . 
Preparation of Fetal Mesencephalic Cell (FMC) 
Suspensions 
Cell suspensions were prepared from the ventral mes­
encephalon of 14-day-old embryos . The mesencephal ic 
area was dissected out as described by Dunnet t and Bjork­
lund (15), incubated at 37°C for 20 min in Du lbecco ' s 
modified essential med ium ( D M E M ) supplemented with 
2 m M glutamine, containing 0 . 0 5 % DNase and 0 . 1 % 
trypsin. The cell suspensions were gently disagregated, 
washed in D M E M , and sedimented by centrifugation. 
Cells were resuspended in 5 ul of D M E M per piece and 
embryo (17). The final concentrat ion was adjusted to 
100,000 cell/ul with D M E M . In some exper iments , sus­
pensions of F M C were preincubated for 3 h with NT-3 
or G D N F (both at 50 ng/ml , from RBI , Natick, M A ) or 
in med ium without neurotrophins. T o evaluate the via­
bility of the cell suspensions, the percentage of surviving 
cells was determined by f luorescence microscopy with 
acridine/ethidium bromide (1:1), as described (15). 
Transfected Fibroblasts 
Rat 3T3 fibroblasts (American Type Culture Col lec­
tion, Manassas , V A ) overexpress ing NT-3 (4) or G D N F 
(5), and mock-transfected fibroblasts were used. Trans­
fected 3T3 cells were grown in D M E M supplemented 
with 10% fetal calf serum, 1 mg/ml penicil l in/strepto­
mycin , 1 mg/ml glutamine, and 200 ug /ml G-418 at 
37°C and 5 % C 0 2 . Cells in active growth phase were 
washed and collected in serum-free med ium at a concen­
tration between 0.5 and 2.0 x 10 5 cells per microli ter for 
grafting. 
Grafting 
Three weeks after the 6 - O H D A lesion of the medial 
forebrain, animals were grafted with a suspension of fe­
tal mesencephal ic cells introduced into the right striatum 
(coordinates A: +0.7 , L: - 3 . 2 ; H: - 5 , from bregma) with 
a flow rate of 1 u l /min, according to one of the follow­
ing procedures: 
a. 3 pi of suspensions containing about 400 ,000 F M C 
was implanted after preincubation for 3 h at 37°C in 
a shaking bath with or wi thout NT-3 or G D N F (50 
ng/ml in both cases) . Four animals were used in each 
group: F M C without neurotrophins , F M C + N T - 3 , 
and F M C + G D N F 
b . 4 ul of a mixture containing F M C and 3T3 was im­
planted in the right striatum. Different proport ions of 
F M C and 3T3 were assayed (1.5 x 10 5 :2 x 10 5 and 3 
x 10 s : 1.5 x 10 5 ), in a final injected vo lume of 4 ul . 
Four animals were used in each group . Animals im­
planted only with F M C , mock-transfected 3T3 , and 
F M C + mock-transfected 3T3 were used as controls . 
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Animals were processed in all cases for the study of 
dopaminergic cell survival, 7 days after grafting, in or­
der to avoid excessive proliferation of the fibroblasts. 
TH Immunocytochemistry 
The animals were anesthet ized and perfused trans-
cardially with 4 % paraformaldehyde in phosphate 
buffer. The brains were rapidly removed and postfixed 
for 24 h, and selected coronal sections were embedded 
in paraffin. Sect ions (5 p m ) through the substantia nigra 
or the striatum were processed for tyrosine hydroxylase 
immunocytochemis t ry and developed with the avidin-bi-
ot in-peroxidase method (Vectastain, A B C Kit from Vec­
tor). Briefly, t issue sections of rat brain were treated 
with 0 . 0 5 % saponin, fol lowed by methanol and hydro­
gen peroxide, and finally normal horse serum. The sec­
tions were incubated overnight at 4 °C with an anti-TH 
monoclonal ant ibody (Sigma) , at a dilution 1:200. The 
peroxidase reaction was visualized with 0 . 0 5 % diamino-
benzidine and 0 . 0 1 % hydrogen peroxide. 
Cell Counts and Statistics 
TH-posi t ive neurons were counted in the ipsilateral 
striatum in six sections per animal and in four animals 
per condit ion, at a x 2 5 0 magnification in a Zeiss-Jenalu-
mar microscope . The total number of cells was calcu­
lated according to the vo lume of the graft: approx. 0.06 
m m 3 . For statistical evaluation, data were subjected to 
one-way analysis of variance ( A N O V A ) and D M S post 
hoc test. 
R E S U L T S 
All studies were carried out in 6-OHDA-les ioned ani­
mals . The extent of the lesion was assessed in each ani­
mal by T H immunosta in ing. All animals included in the 
study showed almost comple te loss of T H + cells in the 
ipsilateral substantia nigra. 
Viability of FMC Suspensions Before Grafting 
Because F M C s are known to survive poorly after 
preparation of cell suspensions, we first examined 
whether preincubat ion of F M C s with neurotrophic fac­
tors known to p romote the survival of dopaminerg ic 
neurons could prevent the loss of T H + cells. Preincuba­
tion of F M C s at a concentrat ion of 100,000 cells/pl in 
D M E M at 37°C for 6 h resulted in a decrease in the cell 
viability from 8 5 % to 6 0 % . In contrast, preincubat ion of 































Figure 1. Effects of neurotrophin-3 (NT-3) and glial cell line-derived neurotrophic factor (GDNF) 
on the percentage of viable rat fetal mesencephalic cells in suspension, as assessed by acridine 
orange (see Materials and Methods). Each point is the mean ± SEM of three separate experiments. 
*p < 0.05, **p < 0.01 with respect to the corresponding control values. 
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ng/ml) for 6 h maintained the viability of mesencephal ic 
cell suspensions at about 8 5 % (Fig. 1). 
Survival of Dopaminergic Cells After Preincubation 
With Neurotrophins and Grafting 
Next, we tested whether preincubat ion of F M C s with 
N T - 3 or G D N F enhanced the survival of T H + cells in 
vivo, 1 week after intrastriatal grafting. Pretreatment 
with NT-3 or G D N F (at 50 ng/ml) increased the num­
bers of T H + cells more than fourfold, compared to 
F M C s preincubated wi thout the factor (Figs. 2 and 3), 
suggest ing an early neuronal survival promot ing effect 
of NT-3 and G D N F on T H + cells grafted in the host 
striatum. 
Survival of Dopaminergic Cells Co-Grafted With 
Transfected Fibroblasts 
T o examine whether constantly del ivered NT-3 or 
G D N F in vivo was more efficient in prevent ing the loss 
of T H + cells grafted in the host striatum, we performed 
co-grafts of F M C s and fibroblast cell l ines known to 
express h igh levels of recombinant , biologically active 
N T - 3 (4) and G D N F (5). One week after grafting a mix­
ture of F M C s and transfected 3T3 fibroblasts (2:1), the 
survival of T H + cells in the striatum was significantly 
increased by both G D N F - and NT-3-transfected fibro­
blasts, compared with mock-transfected fibroblasts or 
F M C s alone (Fig. 4) . All the measures were performed 
1 week after grafting, when only small tumors and focal 
damage were caused by the fibroblasts. F igure 5A shows 
the appearance of an implant of F M C s plus fibroblasts, 
1 week after intrastriatal grafting. The survival of dopa­
minergic cells was much higher in co-grafts with N T - 3 -
producing fibroblasts. This effect was also observed 
when different ratios of F M C s and 3T3 cells were co-
grafted (Table 1). Grafting of a larger number of 3 T 3 -
N T - 3 cells resulted in a slightly higher number of sur­
viving T H + cells compared to the total number of cells 
grafted (0 .9% and 0 .6% when 200 ,000 or 150,000 3 T 3 -
NT-3 cells were grafter, respectively). In G D N F - p r o d u c -
ing grafts, the number of T H + cells was lower than in 
NT-3-produc ing grafts, but a marked increase in T H + 
fibers was observed in the host striatal t issue surround­
ing the implant (Fig. 5C) at a dis tance of about 525 u m 
from the border of the graft. 
DISCUSSION 
M a n y studies have suggested that graft survival in a 
host brain depends , a m o n g other parameters , on the ac­
cess of transplanted neurons to growth factors (34). Here 
we describe, by two different procedures , a significant 
improvement in T H + F M C survival mediated by two 
neurotrophic f ac to r s—NT-3 and G D N F — a t relatively 
short t imes after transplantation (1 week) . This per iod 








CONTROL GDNF NT3 
Figure 2. Preincubation of fetal mesencephalic cells for 3 h with NT-3 (50 ng/ml) or GDNF (50 
ng/ml), but not vehicle (DMEM, control), increased the number of tyrosine hydroxylase-positive 
neurons 7 days after striatal grafting. The results are the mean ± SEM of four animals for each 
group. Significances were determined by ANOVA, F(3, 12) = 4.08, p = 0.03, and post hoc DMS 
test (*p < 0.05, **p < 0.01 compared with controls). 
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Figure 3. Microphotographs of tyrosine hydroxylase-positive 
neurons in-striatal grafts of fetal mesencephalic cells, 7 days 
after grafting and preincubation with (A) DMEM without neu­
rotrophic factors, (B) medium containing neurotrophin-3 (50 
ng/ml), or (C) medium containing glial cell line-derived neuro­
trophic factor (50 ng/ml). Sections were counterstained with 
hematoxylin. Scale bar = 50 urn. 
has been chosen to avoid an excessive proliferation of 
the transfected fibroblasts and compress ion of the F M C . 
Thus , our results suggest that cells other than fibroblasts 
might be better suited to implement for clinical use and 
to exploit the beneficial effect of G D N F and NT-3 on 
fetal cells after transplantation. 
The expression of both NT-3 (38) and its receptor, 
t rkC (30), is high during fetal development (between 
E14 and E l 6 ) but reduced in the adult brain. NT-3 is 
expressed in many brain areas, including the mesen­
cephalon and striatum, during the perinatal period (32). 
NT-3 immunoreact ivi ty has been detected both in glia 
and neuronal populat ions of developing substantia nigra 
(58), and it has been shown to increase the survival of 
ventral mesencephal ic dopaminergic neurons in pr imary 
cultures (27). Our data also suggest that NT-3 is a sur­
vival factor for embryonic dopaminergic neurons in 
vivo, because preincubation of immature dopaminergic 
cells with N T - 3 , or direct supply of NT-3 to grafted 
F M C s in vivo, enhances the survival of T H + cells in the 
host brain. 
In addition, G D N F was initially characterized by its 
ability to promote the survival of mesencephal ic dopa­
minergic neurons in vitro (37), and more recently, it was 
reported to reduce the apoptosis of dopaminergic neu­
rons (14). Because G D N F is also expressed in the devel­
oping striatum and mesencephalon (49,52,54), and be­
cause its receptors, the proto-oncogene c-ret and the co-
receptor GFRocl, are present in developing nigral neu­
rons (54,55,57), it has been suggested that G D N F plays 
a trophic role in the developing nigrostriatal system. In 
the adult brain, G D N F m R N A is expressed at low levels 
both in the substantia nigra and in the striatum (5,47), 
suggesting a possible local and target-derived role of 
G D N F in the support of striatal and dopaminergic neu­
rons. Interestingly, mechanical injury increases G D N F 
expression in the striatum (36), and administrat ion of 
G D N F in vivo protects striatal neurons (41). Moreover , 
the degenerat ion of nigrostriatal dopaminergic neurons 
can also be prevented in vivo by direct injection of 
G D N F protein (20,45,52), adenovirus-mediated G D N F 
gene transfer (7,9,13,39), or cel l -mediated delivery of 
G D N F (1,41). 
Our results show that t reatment of F M C s with NT-3 
or G D N F prior to or during grafting enhanced the sur­
vival of dopaminergic neurons in the striatum. Indeed, 
the exposure of F M C s to trophic factors maintains in 
vitro their viability at least 6 h (Fig. 1), and the in vivo 
survival of the dopaminergic cells, 1 week after grafting 
into the brain, was fourfold higher than that of non-pre-
incubated cells (Fig. 2). That indicates that prior treat­
ment of a cell suspension at early stages with trophic 
factors is crucial for the late survival of these cells. 
Al though both neurotrophic factors were beneficial, 
surprisingly, cont inuous administrat ion of NT-3 in vivo 
was more effective than G D N F in maintaining the sur­
vival of dopaminergic neurons after grafting. Many 
studies have examined the beneficial effects of pretreat­
ment or t reatment of F M C s with neurotrophic factors in 
vivo. Coadminis t ra t ion of G D N F and F M C s (3,19,50) 
or administrat ion of G D N F in the vicinity of the intra­
striatal (19,43,46,48) or nigral (51,56) F M C grafts has 
been shown to: (a) p romote the survival and sprouting 
of T H + neurons from F M C s grafted either in the stria-
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Figure 4. Co-grafting of 300,000 fetal mesencephalic cells (FMC) and 150,000 fibroblasts overex-
pressing neurotrophin-3 (NT3-3T3) or glial cell line-derived factor (GDNF-3T3), but not mock-
transfected fibroblasts (mock-3T3), increased the number of surviving tyrosine hydroxylase-posi-
tive neurons in the rat striatum compared to the grafting of FMCs alone. The results are the mean 
+ SEM of four animals for each group. Significances were determined by ANOVA, F(3, 12) = 6.3, 
p = 0.005, and post hoc DMS test (*p < 0.05, **p < 001, compared with FMC values). 
B 7 » v ' 
Figure 5. Distribution of TH immunostaining in striatal co-grafts of 300,000 fetal mesencephalic cells (FMCs) and (A) 150,000 
mock-transfected fibroblasts, (B) NT-3-producing fibroblasts, or (C) GDNF-producing fibroblasts. Arrow in (A) indicates the posi­
tion of the graft. Asterisks and arrowheads in (B) indicate the position of fibroblasts and high density of TH+ neurons, respectively. 
Note in (C) the increase in TH immunoreactive fibers (brackets) surrounding the graft of FMCs and GDNF-producing fibroblasts. 
Sections were taken 7 days after grafting and were counterstained with hematoxylin. Scale bars = 100 um. 
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Table 1. Number of TH+ Neurons in the Rat Striatum After Co-Grafting of Different 
Amounts of Fetal Mescephalon Cells (FMC) and Neurotrophin-3 (NT-3) or Mock-Transfec-
ted-3T3 Cells per Graft 
FMC + 3T3/NT-3 FMC + 3T3/Mock 
150,000 FMC + 200,000 3T3 1303 + 233* (10.8%) 92 ± 30 (0.8%) 
300,000 FMC + 150,000 3T3 1905 + 387* (7.9%) 2 8 7 1 9 2 (1.2%) 
Percentages refer to surviving TH+ cells with respect to the dopaminergic cells grafted (8% of the total 
FMCs). 
*p < 0.01 compared with mock-transfected 3T3 co-grafts; n = 4 for each group. 
tum or in the substantia nigra, and (b) to improve motor 
asymmetry in 6-OHDA-les ioned animals . Al though 
other neurotrophic factors, such as B D N F , improve be­
havioral performance, they have not shown increased 
survival or sprouting from T H + F M C s (44,51,59) . It has 
also been reported that NT-4 , but not N T - 3 , induces 
sprouting and behavioral recovery from 6 - O H D A le­
sions (21). However , there is a discrepancy concerning 
the effects of NT-3 as a survival factor for T H + neurons 
derived from F M C s (21,27). Whi le t reatment of F M C s 
with NT-3 promotes the survival of T H + cells in vitro 
(27) and in vivo (present results), in t raparenchymal in­
jec t ions of N T - 3 failed to enhance the survival of the 
T H + cells in the grafts (21) . Thus , our results suggest 
that the constant and local delivery of N T - 3 , newly 
m a d e and del ivered by the cell line, is more effective at 
mainta ining T H + F M C s . 
Interestingly, and unlike the effects of N T - 3 , our re­
sults also show that G D N F is able to induce sprouting 
of T H + fibers in the host striatal t issue surrounding the 
graft of F M C + G D N F - 3 T 3 . These findings are consis­
tent with previous reports showing the induction of 
sprouting of T H + F M C s by G D N F (3,19,43,45,48, 
50,51,56) , but not by NT-3 (21). Similar effects on do­
paminergic neuron sprouting have been described for 
GDNF-express ing fibroblasts grafted either in the stria­
tum or the substantia nigra (1,41). Moreover , because 
high doses of G D N F (or proximity to the G D N F graft) 
are required for the induction of sprouting of T H + fibers 
(1,5), our results suggest that high levels of G D N F were 
available in the t issue, and that differences be tween 
G D N F and NT-3 reflect either differences in the respon­
siveness of T H + cells at a certain deve lopment stage 
or diverse biological activities of these molecules . Both 
G D N F and N T - 3 may act sequentially on developing 
dopaminerg ic neurons to sculpt their final mature pheno­
type. In that case, strategies including a sequential treat­
ment of F M C s with neurotrophic factors or exposure of 
F M C s to a combinat ion of factors, including G D N F , 
N T - 3 , and probably others like B D N F (2,35,44,59), ei­
ther before and dur ing the early phases of transplanta­
tion, may enhance the survival, integration, and perfor­
mance of dopaminerg ic cells in the host brain. In that 
way, NT-3 and G D N F could thus be candidates for the 
transplantational t reatment of Park inson ' s disease. 
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